Back to Search
Start Over
HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
- Source :
- Infection. 47:293-300
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.
- Subjects :
- Adult
Male
0301 basic medicine
Microbiology (medical)
Drug
Hepatitis B virus
medicine.medical_treatment
media_common.quotation_subject
030106 microbiology
Hbv reactivation
medicine.disease_cause
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Hbsag negative
Germany
medicine
Humans
030212 general & internal medicine
Aged
Retrospective Studies
media_common
Chemotherapy
Hepatitis B Surface Antigens
business.industry
virus diseases
General Medicine
Middle Aged
Hepatitis B
medicine.disease
Hepatitis B Core Antigens
digestive system diseases
Anti hbc
Infectious Diseases
Antirheumatic Agents
Immunology
Drug Therapy, Combination
Female
Virus Activation
Rituximab
business
medicine.drug
Subjects
Details
- ISSN :
- 14390973 and 03008126
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Infection
- Accession number :
- edsair.doi.dedup.....b6018620ad5c6c78f34d8fdec670e1ea